Search results
Results from the WOW.Com Content Network
Sorrell v. IMS Health Inc., 564 U.S. 552 (2011), [1] is a United States Supreme Court case in which the Court held that a Vermont statute that restricted the sale, disclosure, and use of records that revealed the prescribing practices of individual doctors violated the First Amendment.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Gonzales v. Oregon, 546 U.S. 243 (2006), was a landmark decision of the US Supreme Court which ruled that the United States Attorney General cannot enforce the federal Controlled Substances Act against physicians who prescribed drugs, in compliance with Oregon state law, to terminally ill patients seeking to end their lives, commonly referred to as assisted suicide. [1]
Texas Attorney General Ken Paxton (R) filed a lawsuit Wednesday accusing a second doctor of violating a state law banning gender-affirming care for transgender minors. The lawsuit, filed in a ...
CVS and Walgreens. $10.7 billion. CVS and Walgreens have agreed to settle lawsuits brought against the companies by several states for their alleged role in the opioid crisis. CVS would pay nearly ...
In January 2009, the United States Court of Appeals for the Second Circuit ruled that the Nigerian victims and their families were entitled to bring suit against Pfizer in the United States under the Alien Tort Statute. Pfizer subsequently settled the case out of court with a $75 million settlement that was subject to a confidentiality clause. [6]
It will also bring the total settlement amount for all of the legal cases against him to nearly $1 billion. The settlement follows a $380 million settlement with both USA Gymnastics and the U.S ...
AstraZeneca plc misrepresented the dates of invention of a stomach ulcer drug, omeprazole (its brand was Losec), to national patent offices and courts.It also deregistered a capsule version, to get longer patent protection, and thus prevent other companies producing generic versions of the drug.